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Monofunctional platinum(II) complexes, such as phenanthriplatin and 
pyriplatin, have notably different characteristics from the bifunctional anticancer 
complexes, such as cisplatin and oxaliplatin, which have detrimental toxicities 
and resistance associated with them. The unique properties of the 
monofunctional complexes may be exploited to target cancer cells without 
producing the toxic side effects associated with the current FDA-approved 
platinum-based anticancer drugs. To advance the understanding of these 
monofunctional platinum(II) complexes, this study replaced the chloride leaving 
ligand with an acetate group, which should increase solubility and alter the rate of 
reactivity with key amino acid and nucleotide targets. Phenanthriplatin and 
pyriplatin compounds were reacted with silver acetate to form insoluble silver 
chloride and the desired complex. Proton nuclear magnetic resonance (1H NMR) 
spectroscopy was used to characterize the new complexes and conduct kinetic 
assays with guanosine 5'-monophosphate (5’-GMP). A rate constant of 2.9 (± 
0.7) x 10-2 M-1s-1 was determined for the reaction between pyriplatin and 5’-GMP, 
previously. A preliminary rate constant of 1.8 (± 0.1) x 10-2 M-1s-1 was determined 
for the newly synthesized cis-[Pt(NH3)2(py)OAc]+ complex with 5’-GMP. Ligand 
exchange kinetics directly influences the anticancer activity and toxicity of 
platinum drugs. Initial results indicate that the solubility is increased, and the rate 
of reaction is decreased by the acetate ligand.
1 
 
1.  INTRODUCTION 
1.1  History of Platinum(II) Complexes 
 Platinum(II)-based anticancer complexes are among the most commonly 
used for the treatment of a variety of cancers; such as cervical, colorectal, lung, 
ovarian, and testicular cancers.1 The Food and Drug Administration (FDA)-
approved anticancer complexes cisplatin [cis-diamminedichloroplatinum(II)], 
oxaliplatin [(R,R)-1,2-diaminocyclohexane)oxalatoplatinum(II)], and carboplatin 
[cis-diammine(1,1′-cyclobutanedicarboxylato)platinum(II)] (Figure 1) are currently 
the most effective chemotherapies in clinical use, and are foundational in cancer 
treatment.2 
 
Figure 1. FDA-approved bifunctional platinum(II) anticancer complexes. 
 
However, there are some critical problems associated with the use of 
these anticancer complexes, including cumulative toxicities of hepatotoxicity 
(chemically driven liver damage), nephrotoxicity (toxic effects on renal function), 
ototoxicity (toxic effects on the auditory nerve), and neurotoxicity or peripheral 
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neuropathy (damage to the peripheral nerves);3 as well as acquired and intrinsic 
resistances, which are a consequence of reduced cellular uptake, intracellular 
changes, replicative bypass mechanisms, increased repair, and altered apoptotic 
pathways.4 Two important research objectives have emerged in order to 
circumvent these detrimental effects: devising novel anticancer complexes with 
reduced toxicities and resistances, as well as increasing the knowledge of the 
mechanisms of action of these novel complexes. Particularly of interest are the 
mechanisms of action by which DNA-platination occurs; such as aquation 
reactions, anation reactions, biotransformation reactions with biologically relevant 
nucleophiles, and degradation reactions.5,6 
1.2  Bifunctional Platinum(II) Anticancer Complexes 
 The cytotoxic action of the bifunctional complexes arises from their 
interaction with DNA, and their ability to form thermodynamically stable bidentate 
Pt-DNA adducts. Once the complex enters the cell, it is activated through an 
aquation reaction, where the leaving ligand is replaced by a molecule of water. 
The water molecule is then subsequently replaced in the reaction with DNA, 
forming a covalent bond with DNA at the N7 position of guanine, the N1 or N7 
position of adenine, or minimally the N3 position of cytosine.7  These platinum(II) 
complexes have been found to bind predominantly to the N7 position of guanine, 
which is more accessible than the positions on adenine and cytosine. 
Furthermore, the N7 position of guanine is the most reactive nucleophilic site on 
DNA, which aids the electrophilic assault by a platinum(II) complex.8 
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The aquated form of the platinum complex initially binds covalently to DNA 
to form a monodentate adduct, followed by a subsequent reaction to form the 
bidentate adduct (Figure 2) in the form of a (GA)-1,2-intrastrand cross-link, (GG)-
1,2-intrastrand cross-link, or (GC)-interstrand cross-link. The primarily observed 
structure was found to be the (GG)-1,2-intrastrand cross-link.9,10 The result of this 
adduct formation is the distortion of DNA, upwards of 55 degrees, which leads to 
several downstream biological effects, most notable of which is transcription 
inhibition and eventually the initiation of apoptotic pathways.11  
 
 




The process of forming this primary platinum(II)-DNA adduct is controlled 
kinetically, rather than thermodynamically. The aquation reaction is the rate-
determining step in the overall reaction. As a result of the elevated concentration 
of chloride ions in both the blood and extracellular fluid, the complex remains 
neutral in these areas.12 The complex is then passively diffused into the cell or 
carried into the cell via mediated active transport, where the aquation of the 
complex is promoted as a result of the significantly lower cellular concentration of 
chloride ions, thereby activating the complex.12 The activated complex then 
proceeds to assault the nucleophilic sites previously mentioned.  
However, only a fraction of the platinum compound that is administered 
reacts with DNA; the DNA-platination reactions discussed previously (anation, 
biotransformation, and degradation) are competing reactions, and therefore, the 
majority of the administered drug binds to extracellular and intracellular amino 
acids.13 Platinum(II) is thiophilic, rendering the amino acids cysteine and 
methionine highly reactive ligands.14 The adducts formed between the platinum 
complex and these proteins are considered to be a significant contributor to 
platinum resistances and toxicities, given that many of the interactions are 
irrevocable.15 Reedijk and coworkers16 studied the role that proteins play in drug 
distribution and metabolism. They discovered that these platinum(II) complexes 
translocate from the sulfur atom of S-guanosyl-L-homocysteine to the guanine N7 
position.16  Moreover, Pinato and colleagues14 characterized the reactivity profile 
of four different bifunctional platinum(II) complexes with three distinct proteins, to 
identify the physiological significance that these processes have as a transitional 
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step in forming the platinum(II)-DNA adducts.  They discovered that the reactions 
between the studied complexes and the chosen proteins promoted 
oligomerization of the proteins, which led them to hypothesize that these 
interactions may be connected to platinum(II) anticancer drug nephrotoxicity.14 
Additionally, by examining the platination reactions between DNA and proteins, in 
addition to examining platinated proteins as the potential reactive entity, the 
researchers determined that a transfer reaction can occur, leading to the DNA 
adduct as the final product.14 
1.3  Monofunctional Platinum(II) Anticancer Complexes 
With the knowledge gained in the studies of bifunctional platinum(II) 
complexes, and in response to the complications associated with the current 
FDA-approved anticancer drugs, many different strategies have been employed 
for the development of novel anticancer drugs and delivery methods to treat 
cancer without the detrimental side effects. The development of novel 
compounds that have specific selectivity in regard to biologically relevant 
nucleophiles with decreased toxicities and resistances has become a 
considerably important research objective, and one such response has been the 
development of monofunctional platinum(II) compounds. These compounds differ 
from the bifunctional compounds in several ways. For instance, they are larger 
and more hydrophobic than the bifunctional complexes due to the replacement of 
one of the chloride ions with a large N-heterocyclic ammine ligand. This alteration 
renders them positively charged, and results in the formation of a monodentate 
DNA adduct.  
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Pyriplatin (cis-[Pt(NH3)2(pyridine)Cl]+) and its derivatives (Figure 3) exhibit 
an altered spectrum of activity and have noteworthy antitumor properties.17,18 
Lovejoy and coworkers19 conducted experiments that revealed increased 
pyriplatin accumulation in cells with increased expression of organic cation 
transporters I and II. This led to the conclusion that these transporters mediate 
the uptake of pyriplatin, and therefore, that pyriplatin may be used to selectively 
target cancerous cells that have organic cation transporter expression while 
reducing the toxic side effects in cells that do not express or have less 
expression of organic cation transporters.19 The researchers also analyzed 
pyriplatin DNA-binding characteristics utilizing x-ray diffraction; it was concluded 
that pyriplatin binds to the DNA duplex and forms a monodentate lesion, 
predominantly at the guanine N7 position, without distorting the DNA duplex.19 
 
Figure 3. Monofunctional platinum(II) anticancer complexes. 
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An x-ray structure of the transcription machinery RNA polymerase II (RNA 
Pol II) halted at the pyriplatin-DNA lesion, was provided by Wang et al.18 The 
stalled RNA Pol II was discovered to be a result of the use of RNA cytidine 
triphosphate (CTP) complemented to the impaired guanine residue.18 This 
revealed that that RNA Pol II halts after the incorporation of CTP at the site of 
damage, resulting in the rotation of the altered guanine residue into the RNA Pol 
II active site, halting transcription beyond the damage site.18 This transcription 
inhibition mechanism is significantly different from that of the traditional 
bifunctional compounds.  Additionally, Zhu and coworkers20 determined that 
pyriplatin binds as effectively to DNA, is as efficient at inhibiting transcription, and 
is detected and repaired by cellular repair machinery with less efficiency than the 
parent compounds. This is an important distinction, owing to the relationship 
between the efficacy of anticancer platinum(II) drugs and transcription 
inhibition.21 
Unfortunately, pyriplatin was found to be more than ten times less 
cytotoxic than cisplatin and oxaliplatin. However, due to the distinctive 
characteristics discovered for pyriplatin, experiments were conducted by Park 
and colleagues1 to improve both the effectiveness and uptake of monofunctional 
platinum(II) complexes through the substitution of the pyridine ligand in pyriplatin 
with different N-heterocyclic ammine ligands. Utilizing the knowledge of the 
mechanism of transcription inhibition discovered by Wang et al.,18 the 
researchers formulated the hypothesis that increasing steric bulk of the N-
heterocyclic ammine ligand would more effectively hinder the advancement of 
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RNA Pol II.1 Two different substitutions, phenanthridine and quinoline for 
pyriplatin, yielded two novel complexes named phenanthriplatin (cis-
[Pt(NH3)2(phenanthridine)Cl]NO3) and quinoplatin (cis-
[Pt(NH3)2(quinoline)Cl]NO3). The characterization of these compounds led to the 
discovery that their coordination geometry is square-planar and that the plane of 
the aromatic N-heterocyclic ligand is perpendicular to the platinum coordination 
plane. This particular orientation provides protection from an axial nucleophilic 
attack perpendicular to the coordination plane; an attack in which the majority of 
substitution reactions occur.1 Therefore, it is feasible that this particular 
orientation would lead to a reduction in ligand exchange reactions, and thereby 
prevent premature deactivation.1 
Cytotoxic effects of their newly developed monofunctional platinum(II) 
complexes were determined using the MTT assay. The results obtained from 
these assays suggested that by increasing the ammine ligand bulk on the 
monofunctional compound, the cytotoxicity of the compound would also be 
improved; indicating a direct correlation between steric bulk and drug efficacy.1 
Park et al.1 directly compared IC50 values for phenanthriplatin, pyriplatin, 
cisplatin, and oxaliplatin in various cell lines. The researchers found 
phenanthriplatin to be between four and forty times more cytotoxic than either of 
the parent compounds, cisplatin and oxaliplatin.1 Furthermore, IC50 values were 
obtained from MTT assays performed seventy-two hours after treatment with the 
compounds phenanthriplatin and cisplatin, in both healthy and cancerous lung 
fibroblasts.1 These values were used to evaluate the selectivity of cancer cells 
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over healthy cells; it was determined that phenanthriplatin exhibited increased 
selectivity toward cancerous cells over healthy cells, as indicated by an IC50 ratio 
value of 3.9, as opposed to cisplatin’s value of 0.9.1  
In an attempt to understand the potent anticancer activity exhibited by 
phenanthriplatin, Park et al.1 monitored the platinum distribution within cancer 
cells that were treated with a concentration of five micromolar cisplatin, 
phenanthriplatin, and pyriplatin, for three hours. They determined that 
phenanthriplatin is taken up more effectively by cells than either of the other two 
compounds.1 They attributed this to the large hydrophobic ligand, 
phenanthridine, which is thought to aid in the transport of the compound across 
the cell membrane, thereby increasing its cytotoxicity.1 Further exploration of 
transcription inhibition processes by phenanthriplatin was carried out utilizing a 
GLuc colorimetric assay. The results demonstrated that in the cancer cell lines 
tested, phenanthriplatin inhibited transcription to an equivalent degree as 
cisplatin, and that pyriplatin inhibited transcription to a lesser degree than either 
cisplatin or phenanthriplatin.1,22,23 
1.4  Previous Work and Current Approach 
 We have recently conducted kinetic assays (Figure 4) with guanosine 5’-
monophosphate (5’-GMP), a biologically relevant nucleophile, and IC50 statistical 
analyses for the parent compound cisplatin, as well as the monofunctional 
complexes [Pt(diethylenetriamine)Cl]+ ([Pt(dien)Cl]+), [Pt(N,N-diethyldiethylene-
triamine)Cl]+ ([Pt(Et2dien)Cl]+), phenanthriplatin, and pyriplatin in four cancer cell 
types (Figure 5). These studies have revealed that the reactions between 
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pyriplatin and phenanthriplatin, individually, with 5’-GMP were over an order of 
magnitude slower, relative to cisplatin, and that phenanthriplatin produced IC50 
values similar to cisplatin, illustrating strong anticancer activity.24 These results 
are comparable to a previous study that determined phenanthriplatin to be 4 – 40 
times more cytotoxic than either cisplatin or oxaliplatin in the cells lines tested.1  
 
 
Figure 4. Monroe and coworkers’24 kinetic assays between 5’-GMP and A.  [Pt(dien)Cl]+ (starting 
[Pt] of 1 mM). B.  [Pt(Et2dien)Cl]+ (starting [Pt] of 18 mM). C.  Pyriplatin (starting [Pt] of 5 mM). D.  







Figure 5. Monroe and coworkers’24 IC50 values for the given complexes in four cancer cell lines. 
 
Due to the unique characteristics of these monofunctional complexes and 
the strong anticancer activity displayed by phenanthriplatin, it is an important 
research objective to further characterize and elucidate the mechanism of action 
of these compounds. This research objective may yield novel complexes that 
have reduced toxic side effects and may provide a means to target and treat 
specific cancer types that exhibit resistances to the parent compounds. For 
instance, the effects of the leaving ligand on the solubility, reactivity, and 
cytotoxicity of the current monofunctional complexes is of particular interest. By 
exchanging the current leaving ligand for another leaving group, we may analyze 








2.  EXPERIMENTAL 
2.1  Materials Used 
 The following chemicals were purchased from Sigma-Aldrich Chemical 
Company: cis-Diamineplatinum(II) dichloride ≥ 99.9% trace metals basis (Product 
# 479306, CAS # 15663-27-1); Deuterium oxide, 99.9 atom % D (Product # 
151882, CAS # 7789-20-0); Diethyl ether, anhydrous, ACS reagent, ≥ 99.0%, 
contains BHT as inhibitor (Product # 673811, CAS # 60-29-7); Dimethyl 
sulfoxide-d6, 99.9 atom % D (Product # 151874, CAS # 2206-27-1); Ethyl 
alcohol, Pure, 200 proof, anhydrous, ≥ 99.5% (Product # 459836, CAS # 64-17-
5); Methanol, ACS reagent, ≥ 99.8% (Product # 179337, CAS # 67-56-1); Nitric 
acid-d solution, 65 wt. % in D2O, 99 atom % D (Product # 176737, CAS # 13587-
52-5); Phenanthridine, 98% (Product # 157384, CAS # 229-87-8); Silver acetate 
ReagentPlus, 99% (Product # 216674, CAS # 563-63-3); Silver nitrate, ACS 
reagent, ≥ 99.0% (Product # 209139, CAS # 7761-88-8); Sodium acetate, 
ReagentPlus, 99% (Product # 110191, CAS # 127-09-3); Sodium deuteroxide 
solution, 40 wt. % in D2O, 99 atom % D (Product # 176788, CAS # 14014-06-3).  
Molecular Sieve, Type 4A, 1/16 Beads (Product # MX1583G, CAS # 70955-01-0) 
was purchased from Supelco.  The subsequent chemicals were purchased from 
Acros Organics: N,N-Dimethylformamide, 99+%, extra pure (Product # 11622, 
CAS # 68-12-2); Guanosine 5’-monophosphate, disodium salt hydrate, 97% 
(Product # 22660, CAS # 5550-12-9); Pyridine, 99+%, extra pure (Product # 
13178, CAS # 110-86-1). 
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2.2  Synthesis of Platinum(II) Complexes 
a)  Synthesis of cis-[Pt(NH3)2(py)Cl]+ and cis-[Pt(NH3)2(phen)Cl]+ 
The syntheses of the parent complexes were carried out according to Park 
et al.1 Trace metal basis cis-diamineplatinum(II) dichloride, Cisplatin, (300 mg) 
was dissolved in 15 mL of extra pure N,N-Dimethylformamide (DMF). One 
equivalent of silver nitrate (169.8 mg) was then added to the Cisplatin solution. 
The reaction vessel was subsequently stirred at 55°C, under protection from the 
light, for 16 hours. The solution was then syringe filtered, to remove the insoluble 
silver chloride, into a round bottom flask. To the filtrate, 0.9 equivalent of the N-
heterocyclic ammine ligand was added (pyridine for pyriplatin and phenanthridine 
for phenanthriplatin). The reaction vessel was again stirred at 55°C, under 
protection from the light, for 16 hours. The solution was then evaporated to 
dryness using a rotary evaporator, and the resulting residue was dissolved in 30 
mL of methanol, which was then syringe filtered to remove unreacted Cisplatin. 
To purify the complex, the methanol solution was stirred intensely, and 100 mL of 
diethyl ether was added dropwise in order to precipitate the complex. The 
precipitate was then washed twice with 50 mL of diethyl ether each time.  
b)  Synthesis of cis-[Pt(NH3)2(py)NO3]+ 
 Cis-[Pt(NH3)2(py)Cl]NO3 was dissolved in DI water and one equivalent of 
silver nitrate was added. The solution was heated to 55°C, then removed from 
the heat and left stirring, under protection from light, for 24 hours. The solution 
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was then syringe filtered, to remove the insoluble silver chloride, and was 
evaporated to dryness utilizing a rotary evaporator to yield the desired complex. 
c)  Synthesis of cis-[Pt(NH3)2(py)OAc]+ 
 Cis-[Pt(NH3)2(py)OAc]+ was synthesized by dissolving pyriplatin and one 
equivalent of silver acetate, separately, in DI water. Dissolving of the solid was 
aided by stirring with a glass stir rod. Once the two solutions were completely 
dissolved, they were mixed together in an amber bottle to protect from light, and 
a small amount of DI water was used for quantitative transfer of reagents. The 
reaction vessel was then placed onto a stir plate, in an incubator set to 55°C, and 
left to stir for 24 hours. The solution was then removed from the incubator, 
syringe filtered to eliminate the insoluble silver chloride, and allowed to air dry in 
a glass mortar. A small amount of pure, anhydrous, ethanol was added to the 
mortar, and the residue was grinded with a glass pestle to obtain a working solid.  
d)  Synthesis of cis-[Pt(NH3)2(phen)OAc]+ 
 Cis-[Pt(NH3)2(phen)OAc]NO3 was synthesized in the same manner as cis-
[Pt(NH3)2(py)OAc]NO3 stated above. Additionally, cis-[Pt(NH3)2(phen)OAc]OAc 
was synthesized per the method stated above, with the addition of one 






2.3   Sample Preparation 
a)  pH Adjustment Solutions 
All samples were dissolved in D2O for NMR analysis. Solutions used to 
adjust pH prior to NMR analysis were 1% and 10% nitric acid-d in deuterium 
oxide (D2O) as well as 1% and 10% sodium deuteroxide in D2O. The pH was 
observed using an Iq Scientific Iq150 Ph Meter with glass probe. 
b)  Aquation of cis-[Pt(NH3)2(py)OAc]+ 
 For the aquation kinetic experiments, the complex was dissolved in D2O to 
achieve the desired concentration of 5 millimolar (mM). The pH of the solution 
was adjusted to 7, and the solution was equilibrated to 25°C in a water bath for 
15 minutes prior to the start of the experiment. 
c)  Conversion of cis-[Pt(NH3)2(py)NO3]+ to cis-[Pt(NH3)2(py)OAc]+ 
 10 mg of cis-[Pt(NH3)2(py)NO3]+ was dissolved in 5 mL D2O. To this 
solution, 0.5 equivalent of sodium acetate was added. Another 0.5 equivalent 
was added at 24-hour increments until 2.0 equivalents of sodium acetate total 
had been added. Following each addition, an NMR spectrum was obtained.  
d)  Kinetic Experiment between cis-[Pt(NH3)2(py)OAc]+ and 5’-GMP 
 4.29 mg of cis-[Pt(NH3)2(py)OAc]+ and 4.07 mg of guanosine 5’-
monophosphate (5’-GMP) were dissolved separately in D2O, to achieve 10 mM 
solutions in each. Each solution was then adjusted to a pH of approximately 7.00 
with nitric acid-d. The two solutions, plus a vial containing D2O, were placed into 
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a water bath at 25°C for 15 minutes to equilibrate. After the equilibration period, 
and moments before starting the kinetics experiment, the solutions were mixed in 
the following ratio: 500μL cis-[Pt(NH3)2(py)OAc]+, 400 μL D2O, and 100 μL 5’-
GMP; resulting in final concentrations of 5 mM cis-[Pt(NH3)2(py)OAc]+ and 1 mM 
5’-GMP. 
2.4 Nuclear Magnetic Resonance Spectroscopy 
 A JEOL 500-megahertz (MHz) Nuclear Magnetic Resonance (NMR) 
spectrometer and Delta™ NMR Data Processing Software were used for both 
the structural analysis of the newly synthesized complexes and the kinetic 
assays. All samples were dissolved in D2O and single pulse proton (1H) NMR 
spectra were obtained for structural analysis, while a program set to collect a 
spectrum every 10 or 15 minutes for a given duration, keeping the NMR at 25°C, 
was utilized for the kinetic experiments.  
2.5 DynaFit 
 Biokin, Ltd. DynaFit biochemical program was utilized to perform a non-
linear least squares regression of the chemical kinetics and equilibrium data to 







3.  RESULTS 
 The general reaction scheme for both syntheses is illustrated in Figure 6; 
where “Am” is the abbreviation for the ammine ligand and corresponds to either 
phenanthridine or pyridine. 
 
 
Figure 6. Reaction scheme for cis-[Pt(NH3)2(py)OAc]+ and cis-[Pt(NH3)2(phen)OAc]+ 
 
 The structures of the synthesized complexes, without the counter ion 
indicated, are illustrated in Figure 7. 
 
Figure 7. Chemical structures of the newly synthesized complexes. 
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3.1  Characterization of cis-[Pt(NH3)2(py)OAc]+ 
 The first complex synthesized was cis-[Pt(NH3)2(py)OAc]+. 
Characterization of the complex was carried out utilizing proton NMR 
spectroscopy, as described in the experimental section. The first attempt at 
analysis yielded the spectrum shown in Figure 8A and Figure 9A; the images 
correspond to the signal from the hydrogen atoms on the acetate group and the 
aromatic hydrogen signals, respectively.  
 Potassium acetate was dissolved in D2O and was analyzed to determine 
that free acetate in solution presents as a single peak at approximately 1.74 parts 
per million (ppm). In comparing the two spectra, focusing only on the acetate 
signals, it was inconclusive as to whether or not there was acetate bound to 
platinum. However, pyriplatin has one doublet at approximately 8.53 ppm, and 
cis-[Pt(NH3)2(py)OAc]+ produced two doublets in this range, indicating some 
change in structure. 
 With the knowledge that pyriplatin undergoes aquation in solution, the cis-
[Pt(NH3)2(py)OAc]+ sample was left for 24 hours at room temperature before 
another spectrum was obtained, in an attempt to illuminate any structural 
changes. This second set of spectra are shown in Figures 8B and 9B. As the pH 
was altered upon aquation, a second peak in the acetate region was revealed, as 
well as another doublet for cis-[Pt(NH3)2(py)H2O]+ in the aromatic region. An 
overlay of the two spectra is shown for ease of comparison in Figure 8C and 
Figure 9C. Parenthetically, these spectra also illustrate the aquation reaction that 






Figure 8. Acetate signals from the cis-[Pt(NH3)2(py)OAc]+ sample without pH adjustment.  







Figure 9. Aromatic hydrogen signals from the cis-[Pt(NH3)2(py)OAc]+ sample without pH 
adjustment. A. Spectrum obtained at hour zero. B. Spectrum obtained at hour 24. 
C. Overlay of spectra. 
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The appearance of a second acetate signal upon pH change served as 
evidence that there was both free acetate and bound acetate present in the 
sample. However, to further illustrate that at pH 7.0 the two signals appear 
overlapped, and to aid in the determination that the second peak was due to 
bound acetate, a new sample was created. This sample was adjusted to a pH of 
approximately 7.0 and was analyzed using 1H NMR spectroscopy. After 48 hours 
at room temperature the pH was monitored and again adjusted to a pH of 
approximately 7.0, then reanalyzed using 1H NMR spectroscopy. These spectra 
are provided in Figures 10A-B and 11A-B. Figures 10C and 11C are spectra 
overlay for comparison. The shift in ppm observed from the acetate signal was 
due to the slight difference in pH at the time of analysis. The decrease in peak 
height observed was due to diluting the sample in order to read the pH of the 
solution for adjustment.   
A noteworthy observation from comparing the two spectra displaying the 
aromatic portion, the unadjusted pH sample at 24 hours and the adjusted pH 
sample at 48 hours, is that the aquated product was decreased at a pH of 7.0 
than that was observed at the lower pH value. One possible explanation for this 












Figure 10. Acetate signals from cis-[Pt(NH3)2(py)OAc]+ sample 2 with pH adjustment. A. 







Figure 11. Aromatic hydrogen signals from cis-[Pt(NH3)2(py)OAc]+ sample 2 with pH adjustment. 




Furthermore, cis-[Pt(NH3)2(py)NO3]+ was synthesized, per the method in 
the experimental section, and was reacted with sodium acetate incrementally, for 
visualization of the ligand exchange. The initial pH of the solution was 
approximately 5.3; after each addition of sodium acetate the pH was adjusted to 
approximately 5.3 prior to analysis by 1H NMR spectroscopy. This experiment is 
shown in Figure 12, which is an overlay of the spectra obtained at different 
equivalent levels; the peak at approximately 1.74 corresponds to free acetate, 
and the peak at approximately 1.84 corresponds to bound acetate. For the 
reactions with 0.5 and 1.0 equivalent of sodium acetate, a near equal amount of 
bound and free acetate were present. When the equivalent amount was brought 
up to 2.0, excess sodium acetate, the equilibrium was shifted toward the 
products in the reaction scheme provided at the top of Figure 12.  
 
 
Figure 12. Overlay of spectra obtained from the reaction between cis-[Pt(NH3)2(py)NO3]+ 




3.2  Kinetic Assays 
a)  Reaction between cis-[Pt(NH3)2(py)OAc]+ and 5’-GMP 
 In previous experiments, we determined the rate constant for the reaction 
between pyriplatin and 5’-GMP.24 To aid in the determination of the effect that the 
leaving ligand has on the reactivity of the complex, kinetic assays between cis-
[Pt(NH3)2(py)OAc]+ and 5’-GMP were conducted, a preliminary rate constant was 
obtained, and the results were compared to that of the parent complex. The 
specific conditions of the experiment are detailed in the experimental section. 
Figure 13 provides the spectra obtained over the course of the kinetic 
experiment. The disappearance of the unreacted 5’-GMP H8 signal at 
approximately 8.08 ppm and the appearance of a product signal at approximately 
8.87 ppm were monitored utilizing 1H NMR spectroscopy. These peaks were 
integrated and fit to two different models in DynaFit (Figure 14). The first model, 
Figure 14A, was the model used previously for pyriplatin and was first order in 
each reactant; the model corresponds to the reaction scheme illustrated in Figure 
15A. With knowledge from previous research on the aquation of platinum(II) 
complexes, the second model, Figure 14B, was devised after a less than ideal fit 
was observed for the new complex and included a first order aquation step, 
illustrated in Figure 15B. A third model that made the aquation step an 







Figure 13. Aromatic region of the spectra obtained from the kinetic experiment between cis-
[Pt(NH3)2(py)OAc]+ and 5’-GMP. The indicated resonances are from the H8 on 5’-GMP.               
A. Spectrum obtained at zero minutes. B. Spectrum obtained at 90 minutes. C. Spectrum 





























Figure 14. Concentration versus time plots created from the kinetic experiment  
between cis-[Pt(NH3)2(py)OAc]+ and 5’-GMP. A. Pseudo first order kinetic  
model. B. First order aquation step plus pseudo first order kinetics.  
 
Figure 15. Reaction schemes for the formation of the Platinum-GMP adduct. 
A. First order in each reactant. B. First order aquation step followed by first 
order in each reactant. 
 
The following table provides a summary of the rate constants for 
comparison. The previously determined rate constant for the parent complex as 
well as the rate constants obtained from each DynaFit model for the newly 
synthesized complex are provided.  
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Table 1. Rate constants from kinetic assays between 5’-GMP and pyriplatin (cis-
[Pt(NH3)2(py)Cl]+)24 and 5’-GMP and cis-[Pt(NH3)2(py)OAc]+. 
 
Species Label (Figure 15) Rate Constant 
cis-[Pt(NH3)2(py)Cl]+ N/A 2.9 (± 0.7) x 10-2 M-1s-1 
 
cis-[Pt(NH3)2(py)OAc]+  
k1 1.8 (± 0.1) x 10-2 M-1s-1 
k2 3 (± 1) x 10-4 s-1 
k3 3.1 (± 0.7) x 10-2 M-1s-1 
 
b)  Aquation of cis-[Pt(NH3)2(py)OAc]+ 
 A kinetic assay for the aquation of cis-[Pt(NH3)2(py)OAc]+ was carried out 
per the method described in the experimental section and closely resembled the 
kinetic experiment with 5’-GMP. The appearance of the cis-[Pt(NH3)2(py)H2O]+ 
doublet at approximately 8.61 ppm and the disappearance of the cis-
[Pt(NH3)2(py)OAc]+ doublet at approximately 8.54 ppm were monitored using 1H 
NMR spectroscopy. The peaks were integrated, and the values were fit to a 
model in DynaFit (Figure 17) to determine preliminary forward and reverse rate 
constants for the aquation reaction illustrated in Figure 16. The forward rate 
constant obtained was 1.02 (± 0.03) x 10-5 s-1 and the reverse rate constant was 








Figure 17. Concentration versus time plot created from the  
kinetic experiment for the aquation of cis-[Pt(NH3)2(py)OAc]+. 
 
3.3  Characterization of cis-[Pt(NH3)2(phen)OAc]+ 
 The second complex synthesized was cis-[Pt(NH3)2(phen)OAc]+. 
Synthesis was carried out through two different approaches, detailed in the 
experimental section. The first approach led to the formation of cis-
[Pt(NH3)2(phen)OAc]NO3. Characterization of the complex was carried out 
utilizing 1H NMR spectroscopy and the analysis of the newly synthesized 
complex yielded the spectrum shown in Figure 18A. The figure corresponds to 
the signals from the hydrogen atoms on the acetate group, both bound to the 
platinum and free. The cis-[Pt(NH3)2(phen)OAc]NO3 sample was left for 48 hours 
(Figure 18B) and 72 hours (Figure 18C), at room temperature, before additional 
spectra were obtained. Overtime, the peak that corresponds to bound acetate, at 






Figure 18. Acetate signals from the cis-[Pt(NH3)2(phen)OAc]+ sample without  
pH adjustment. A. Spectrum obtained at hour zero. B. Spectrum obtained at  





Figure 18. Continued. 
 
 The second approach to led to the formation of cis-
[Pt(NH3)2(phen)OAc]OAc. This added approach was utilized in an attempt to 
obtain a less hygroscopic solid. Characterization of the complex was again 
carried out utilizing 1H NMR. Analysis of the complex yielded the spectrum shown 
in Figure 19A. The cis-[Pt(NH3)2(phen)OAc]OAc sample was left for 72 hours 
(Figure 19B) at room temperature before an additional spectrum was obtained. 
Overtime, a decrease was once more observed for the peak associated with 





Figure 19. Acetate signals from the cis-[Pt(NH3)2(phen)OAc]OAc sample without pH adjustment. 




4.  DISCUSSION 
 Cis-[Pt(NH3)2(py)OAc]+ was synthesized by a single means and was 
characterized utilizing 1H NMR spectroscopy. Cis-[Pt(NH3)2(phen)OAc]+ was 
synthesized via two different methods and was also characterized using 1H NMR 
spectroscopy. The intention in synthesizing these compounds was to create a 
compound that was more soluble in aqueous liquid, to be more compatible with 
the human body, in addition to altering the reactivity of the complexes. 
Both newly synthesized complexes were more soluble in water; in fact, 
both complexes were made hygroscopic by the addition of the acetate group in 
place of the chloride. This hygroscopicity made the compounds more challenging 
to work with, but nonetheless achieved the solubility goal. It is also the reason 
that two different methods were used in synthesizing cis-[Pt(NH3)2(phen)OAc]+, 
which was even more hygroscopic than cis-[Pt(NH3)2(py)OAc]+. The second 
method of synthesis attempted to not only change the leaving ligand, but to also 
change the counter ion, which has been implicated in affecting the solubility of a 
metal complex. While the second method did not entirely remove the hygroscopic 
nature of the compound, it did seem to decrease it, as a more workable solid was 
obtained.   
 In determining the reactivity of the newly synthesized complex cis-
[Pt(NH3)2(py)OAc]+, kinetic assays were conducted for both the aquation of the 
complex and the reaction of the complex with 5’-GMP. A preliminary rate 
constant of 1.8 (± 0.1) x 10-2 M-1s-1 was determined for the newly synthesized cis-
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[Pt(NH3)2(py)OAc]+, under the same conditions for which the rate constant was 
obtained for the parent complex, cis-[Pt(NH3)2(py)Cl]+. The rate constant 
previously determined for the parent complex with 5’-GMP is                              
2.9 (± 0.7) x 10-2 M-1s-1.  Comparing these two rate constants, initial results 
indicate that the rate of reaction is decreased by the acetate ligand.  
Furthermore, a second model was used to determine the rate constant for 
cis-[Pt(NH3)2(py)OAc]+, which included an aquation step prior to the complex 
reacting with 5’-GMP. The first step of the reaction yielded a rate constant of 2.9 
(± 1.2) x 10-4 s-1, and the second step of the reaction yielded a rate constant of 
3.1 (± 0.7) x 10-2 M-1s-1. A notable observation from this experiment is that the 
rate constant for the second step is approximately equal to that of the parent 
complex, suggesting one of the following: aquation of the chloride on the parent 
complex is not rate-limiting or the displacement of water by guanine is just as fast 
as the displacement of chloride. Additionally, the rate of aquation was determined 
for cis-[Pt(NH3)2(py)OAc]+; the rate constants were 1.02 (± 0.03) x 10-5 s-1 for the 
forward direction and 1.4 (± 0.2) x 10-2 M-1s-1 for the reverse direction.  
Ligand exchange kinetics directly influences the anticancer activity and 
toxicity of platinum drugs, and therefore, further experiments into the effects that 
the leaving ligand has on the reactivity and the toxicity of the complex is 
desirable. It would also be useful to obtain an aquation constant for cis-
[Pt(NH3)2(py)Cl]+, for comparison. Future work should include finishing the kinetic 
assays for both complexes, attempting to synthesize complexes with additional 
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changes to the leaving ligand, a benzoate group for example, and lastly, to 
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6.  ABBREVIATIONS  
Any N-heterocyclic ammine ligand………………………………………………    Am 
cis-[Pt(NH3)2(phen)Cl]+………………………………………………  Phenanthriplatin 
cis-[Pt(NH3)2(py)Cl]+…………………………………………………………   Pyriplatin 
Cytidine triphosphate………………………………………………………………  CTP 
Guanosine 5’-monophosphate………………………………………………    5’-GMP 
Hydrogen nuclear magnetic resonance……………………………………    1H NMR 
N,N-Dimethylformamide…………………………………………………………    DMF 
OAc………………………………………………………………………………  Acetate 
Parts per million……………………………………………………………………   ppm 
Phen……………………………………………………………………   Phenanthridine 
[Pt(diethylenetriamine)Cl]+………………………………………………   [Pt(dien)Cl]+ 
[Pt(N,N-diethyldiethylene-triamine)Cl]+ ……………………………    [Pt(Et2dien)Cl]+ 
Py………………………………………………………………………………    Pyridine 
RNA polymerase II…………………………………………………………   RNA Pol II 
 
 
 
